Log in

NASDAQ:PTX - Pernix Therapeutics Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$0.03
-0.18 (-86.17 %)
(As of 06/25/2019)
Today's Range
$0.02
Now: $0.03
$0.03
50-Day Range
$0.03
MA: $0.16
$0.21
52-Week Range
$0.20
Now: $0.03
$3.30
Volume16,105 shs
Average Volume3.04 million shs
Market Capitalization$419,339.00
P/E RatioN/A
Dividend YieldN/A
Beta1.2
Pernix Therapeutics Holdings, Inc, a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription drugs primarily for the United States market. It targets underserved therapeutic areas, such as central nervous system (CNS), including pain, neurology, and psychiatry. The company's products comprise Zohydro ER with BeadTek, an opioid agonist indicated for the management of pain; Silenor, a non-narcotic, non-scheduled, and non-addictive prescription sleep aid for the treatment of insomnia characterized by difficulty with sleep maintenance; and Treximet, a fixed dose combination product indicated for the treatment of acute migraine. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:PTX
CUSIP71426V10
Phone800-793-2145

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$146.07 million
Book Value($14.77) per share

Profitability

Net Income$-77,140,000.00

Miscellaneous

EmployeesN/A
Market Cap$419,339.00
Next Earnings DateN/A
OptionableOptionable

Receive PTX News and Ratings via Email

Sign-up to receive the latest news and ratings for PTX and its competitors with MarketBeat's FREE daily newsletter.


Pernix Therapeutics (NASDAQ:PTX) Frequently Asked Questions

What is Pernix Therapeutics' stock symbol?

Pernix Therapeutics trades on the NASDAQ under the ticker symbol "PTX."

Has Pernix Therapeutics been receiving favorable news coverage?

Press coverage about PTX stock has trended somewhat negative this week, InfoTrie Sentiment reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Pernix Therapeutics earned a coverage optimism score of -1.9 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Pernix Therapeutics.

Who are some of Pernix Therapeutics' key competitors?

What other stocks do shareholders of Pernix Therapeutics own?

Who are Pernix Therapeutics' key executives?

Pernix Therapeutics' management team includes the folowing people:
  • Mr. John Anthony Sedor, Chairman & CEO (Age 74)
  • Mr. Kenneth R. Pina Esq., Sr. VP, Chief Legal & Compliance Officer and Corp. Sec. (Age 60)
  • Mr. Glenn Whaley, VP of Fin., Principal Financial & Accounting Officer (Age 51)
  • Mr. Anthony M. Orrico, VP of Technical & Supply Operations
  • Mr. George P. Jones, VP of Sales & Marketing

What is Pernix Therapeutics' stock price today?

One share of PTX stock can currently be purchased for approximately $0.03.

How big of a company is Pernix Therapeutics?

Pernix Therapeutics has a market capitalization of $419,339.00 and generates $146.07 million in revenue each year. View Additional Information About Pernix Therapeutics.

What is Pernix Therapeutics' official website?

The official website for Pernix Therapeutics is http://www.pernixtx.com/.

How can I contact Pernix Therapeutics?

Pernix Therapeutics' mailing address is 10 NORTH PARK PLACE SUITE 201, MORRISTOWN NJ, 07960. The specialty pharmaceutical company can be reached via phone at 800-793-2145 or via email at [email protected]


MarketBeat Community Rating for Pernix Therapeutics (NASDAQ PTX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  349 (Vote Outperform)
Underperform Votes:  239 (Vote Underperform)
Total Votes:  588
MarketBeat's community ratings are surveys of what our community members think about Pernix Therapeutics and other stocks. Vote "Outperform" if you believe PTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel